Nosocomial infections create an economic burden on healthcare providers due to increased morbidity and mortality of patients, length of hospital stay, and additional diagnosis and treatment costs. Studies have shown that the hospital infection rate in our country is between 1% and 16.5% (Büke et al., 2005).
Healthcare-associated infections caused by carbapenemase-resistant enteric bacteria are increasing in our country and around the world. In particular, Klebsiella pneumoniae causes bloodstream infections with high mortality due to its carbapenemase-resistant strains. Long-term hospitalization, follow-up in intensive care, receiving broad-spectrum antibiotics, the presence of a central venous catheter, intubation, immunosuppression and the presence of a severe underlying disease are among the factors that increase mortality.
Antibiotic resistance has increased in society due to the excessive use of broad-spectrum antibiotics without a definitive diagnosis in the past, which has caused existing antibiotics to lose sensitivity in some bacterial diseases or to be used in higher doses, indirectly changing their pharmacodynamics.
Especially in bacterial and viral infections, differential diagnosis is one of the steps to reduce unnecessary antibiotic use.
While the CARBA-5 and Colistin rapid resistance tests that we sell provide our physicians with the data to detect and differentiate carbapenemase and colistin resistant infections in a short time and initiate appropriate treatment, the FebriDX rapid test helps to differentiate bacterial infection from viral infection in a short time, thus supporting the rational use of antibiotics.
Kaan Medikal offers reliable solutions with its experience in analytical toxicology application areas, product diversity and effective support.
